{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T20:48:38Z","timestamp":1768078118305,"version":"3.49.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T00:00:00Z","timestamp":1668384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T00:00:00Z","timestamp":1668384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100002873","name":"Chulalongkorn University","doi-asserted-by":"publisher","award":["764002-HE04"],"award-info":[{"award-number":["764002-HE04"]}],"id":[{"id":"10.13039\/501100002873","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Microbiol"],"DOI":"10.1038\/s41564-022-01271-0","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T17:03:23Z","timestamp":1668445403000},"page":"1987-1995","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Safety and immunogenicity of a prefusion non-stabilized spike protein mRNA COVID-19 vaccine: a phase I trial"],"prefix":"10.1038","volume":"7","author":[{"given":"Sivaporn","family":"Gatechompol","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wonngarm","family":"Kittanamongkolchai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chutitorn","family":"Ketloy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eakchai","family":"Prompetchara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arunee","family":"Thitithanyanont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anan","family":"Jongkaewwattana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Supranee","family":"Buranapraditkun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamad-Gabriel","family":"Alameh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sasiwimol","family":"Ubolyam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiratchaya","family":"Sophonphan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanakorn","family":"Apornpong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Kerr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adeeba","family":"Kamarulzaman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarawut","family":"Siwamogsatham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eug\u00e8ne","family":"Kroon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thanyawee","family":"Puthanakit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanitha","family":"Patarakul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanapat","family":"Palaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wassana","family":"Wijagkanalan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexis","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Drew","family":"Weissman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7348-2352","authenticated-orcid":false,"given":"Kiat","family":"Ruxrungtham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"ChulaVAC-001 study team","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,14]]},"reference":[{"key":"1271_CR1","unstructured":"Coronavirus Pandemic (COVID-19) Vaccinations (Our World in Data, 2020)."},{"key":"1271_CR2","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205\u20131211 (2021).","journal-title":"Nat. Med."},{"key":"1271_CR3","doi-asserted-by":"publisher","unstructured":"Prompetchara, E. et al. Immunogenicity and protective efficacy of a sars-cov-2 mrna vaccine encoding secreted non-stabilized spike protein in mice. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2022.09.07.506878 (2022).","DOI":"10.1101\/2022.09.07.506878"},{"key":"1271_CR4","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","volume":"20","author":"N Chaudhary","year":"2021","unstructured":"Chaudhary, N., Weissman, D. & Whitehead, K. A. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat. Rev. Drug Discov. 20, 817\u2013838 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1271_CR5","doi-asserted-by":"publisher","first-page":"139","DOI":"10.15585\/mmwr.mm7104e3","volume":"71","author":"MG Thompson","year":"2022","unstructured":"Thompson, M. G. et al. Effectiveness of a third dose of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of delta and omicron variant predominance - VISION Network, 10 States, August 2021-January 2022. MMWR Morb. Mortal. Wkly Rep. 71, 139\u2013145 (2022).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"1271_CR6","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41586-021-03594-0","volume":"594","author":"KO Saunders","year":"2021","unstructured":"Saunders, K. O. et al. Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. Nature 594, 553\u2013559 (2021).","journal-title":"Nature"},{"key":"1271_CR7","doi-asserted-by":"publisher","first-page":"701501","DOI":"10.3389\/fimmu.2021.701501","volume":"12","author":"D Mart\u00ednez-Flores","year":"2021","unstructured":"Mart\u00ednez-Flores, D. et al. SARS-CoV-2 vaccines based on the spike glycoprotein and implications of new viral variants. Front. Immunol. 12, 701501 (2021).","journal-title":"Front. Immunol."},{"key":"1271_CR8","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1126\/science.1243283","volume":"342","author":"JS McLellan","year":"2013","unstructured":"McLellan, J. S. et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342, 592\u2013598 (2013).","journal-title":"Science"},{"key":"1271_CR9","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1038\/s41591-021-01540-1","volume":"27","author":"S Feng","year":"2021","unstructured":"Feng, S. et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat. Med. 27, 2032\u20132040. (2021).","journal-title":"Nat. Med."},{"key":"1271_CR10","doi-asserted-by":"crossref","unstructured":"Gilbert, P. B. et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy trial. Science 375, 43\u201350 (2022).","DOI":"10.1126\/science.abm3425"},{"key":"1271_CR11","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1038\/s41591-021-01484-6","volume":"27","author":"RA Koup","year":"2021","unstructured":"Koup, R. A. et al. A government-led effort to identify correlates of protection for COVID-19 vaccines. Nat. Med. 27, 1493\u20131494 (2021).","journal-title":"Nat. Med."},{"key":"1271_CR12","unstructured":"Access Consortium: Alignment with ICMRA Consensus on Immunobridging for Authorising New Covid-19 Vaccines. (Access Consortium, 2021)."},{"key":"1271_CR13","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41586-021-04387-1","volume":"602","author":"S Cele","year":"2022","unstructured":"Cele, S. et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature 602, 654\u2013656 (2022).","journal-title":"Nature"},{"key":"1271_CR14","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMc2119641","volume":"386","author":"F Schmidt","year":"2021","unstructured":"Schmidt, F. et al. Plasma neutralization of the SARS-CoV-2 omicron variant. N. Engl. J. Med. 386, 599\u2013601 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1271_CR15","doi-asserted-by":"publisher","first-page":"eabn7842","DOI":"10.1126\/scitranslmed.abn7842","volume":"14","author":"BL Sievers","year":"2022","unstructured":"Sievers, B. L. et al. Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses. Sci. Transl. Med. 14, eabn7842 (2022).","journal-title":"Sci. Transl. Med."},{"key":"1271_CR16","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1016\/S0140-6736(21)02249-2","volume":"398","author":"N Barda","year":"2021","unstructured":"Barda, N. et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet 398, 2093\u20132100 (2021).","journal-title":"Lancet"},{"key":"1271_CR17","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41562-021-01122-8","volume":"5","author":"E Mathieu","year":"2021","unstructured":"Mathieu, E. et al. A global database of COVID-19 vaccinations. Nat. Hum. Behav. 5, 947\u2013953 (2021).","journal-title":"Nat. Hum. Behav."}],"container-title":["Nature Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41564-022-01271-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41564-022-01271-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41564-022-01271-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T12:10:04Z","timestamp":1669810204000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41564-022-01271-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,14]]},"references-count":17,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1271"],"URL":"https:\/\/doi.org\/10.1038\/s41564-022-01271-0","relation":{},"ISSN":["2058-5276"],"issn-type":[{"value":"2058-5276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,14]]},"assertion":[{"value":"28 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In accordance with the University of Pennsylvania policies and procedures and our ethical obligations as researchers, we report that Drew Weissman is named on patents that describe the use of nucleoside-modified mRNA as a platform to deliver therapeutic proteins and vaccines. We have disclosed those interests fully to the University of Pennsylvania, and we have in place an approved plan for managing any potential conflicts arising from licensing of our patents. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}